Skip to main content
. 2017 Apr 27;1:PO.16.00004. doi: 10.1200/PO.16.00004

Fig 2.

Fig 2.

Number of patients with and without potentially US Food and Drug Administration–actionable alterations in each malignancy type. ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MM, multiple myeloma.